MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

REGENXBIO Inc

Suletud

SektorTervishoid

9.19 3.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.48

Max

9.3

Põhinäitajad

By Trading Economics

Sissetulek

8.4M

-51M

Müük

-3M

21M

Aktsiakasum

-1.01

Kasumimarginaal

-241.284

Töötajad

353

EBITDA

17M

-38M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+253.26% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

37M

334M

Eelmine avamishind

5.58

Eelmine sulgemishind

9.19

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

REGENXBIO Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 09:30 UTC

Peamised uudised

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

REGENXBIO Inc Prognoos

Hinnasiht

By TipRanks

253.26% tõus

12 kuu keskmine prognoos

Keskmine 32.5 USD  253.26%

Kõrge 50 USD

Madal 12 USD

Põhineb 11 Wall Streeti analüütiku instrumendi REGENXBIO Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

10

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

7.82 / N/AToetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.